Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Utah Medical Products, Inc.NASDAQ: UTMD

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$130K, compared with $12K a year earlier. Trailing-twelve-month accounts receivables was $191K.

Context

  • Accounts receivables amounted to 0.9% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$130K or moves back toward the trailing-twelve-month quarterly average of $47.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$130K-130.2% QoQ
Last fiscal yearDec 2025
$333K+142.6% YoY
LTMMar 2026
$191K+134.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1183.3%——
1 year+142.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
333K USD
Year-over-year change
+142.6%

Accounts Receivables vs competitors

How UTMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +134.4% is the 3rd highest of 10, against a peer median of -97.4%.
  • Accounts receivables amounts to 0.5% of revenue for UTMD, versus a peer median of 4.2%.
UTMD Competitors
Accounts Receivables for UTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$152.88M USD-20.2%+92.8%326.1%
STIMNeuronetics, Inc.LTM Mar 2026$7.18M USD+294.6%—4.7%
NYXHNyxoah S.A.LTM Mar 2026€5.03M EUR-442.9%—30.8%
PROFProfound Medical Corp.LTM Mar 2026$3.49M USD-927.9%-50.3%18.5%
OSUROraSure Technologies, Inc.LTM Mar 2026$3.09M USD-125.5%—2.7%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$2.79M USD+263.9%+70.2%3.7%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$440K USD-119.2%—71.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$191K USD+134.4%—0.5%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$108K USD+104.2%—0.1%
PREPrenetics Global LimitedLTM Mar 2026$74K USD——0.1%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$33.12K USD-97.4%+30.5%0.1%
Peer median (excluding UTMD) —-97.4%+50.4%4.2%

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income14.79M16.47M16.64M13.87M11.29M
Depreciation & Amortization7.28M7.08M6.37M2.85M3.01M
Deferred Income Tax(92K)(401K)(681K)(338K)(659K)
Stock-Based Compensation166K183K225K256K373K
Change in Working Capital(1.01M)(2.23M)(233K)(1.8M)317K
Accounts Receivables(1.13M)(525K)2.27M(781K)333K
Inventory(485K)(2.35M)(670K)587K1.2M
Accounts Payables(23K)464K(456K)(73K)211K
Other Working Capital632K188K(1.38M)(1.54M)(1.42M)
Other Non-Cash Items63K36K(33K)(4K)367K
Operating Cash Flow21.2M21.15M22.28M14.83M14.69M
Capital Expenditures(552K)(818K)(639K)(235K)(371K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(9K)027K0
Investing Cash Flow(552K)(818K)(639K)(208K)(371K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0(2.5M)0(19.97M)(8.36M)
Dividends Paid(11.47M)(3.16M)(4.28M)(4.26M)(3.98M)
Other Financing Activities560K174K117K390K0
Financing Cash Flow(10.91M)(5.48M)(4.17M)(23.84M)(12.34M)
Effect of Forex Changes(362K)(767K)339K(677K)797K
Net Change in Cash9.38M14.08M17.82M(9.89M)2.78M
Free Cash Flow20.65M20.33M21.64M14.6M14.32M

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.